Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Cash from Financing Activities (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Cash from Financing Activities for 9 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 240400.0% to $2.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.8 million through Dec 2025, down 45.25% year-over-year, with the annual reading at $9.8 million for FY2025, 45.25% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $2.4 million at Rein Therapeutics, up from $1.9 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $55.6 million in Q1 2021, with the low at -$446000.0 in Q3 2024.
  • Average Cash from Financing Activities over 4 years is $8.3 million, with a median of $1.3 million recorded in 2025.
  • The sharpest move saw Cash from Financing Activities crashed 99.99% in 2024, then surged 240400.0% in 2025.
  • Over 4 years, Cash from Financing Activities stood at $1000.0 in 2021, then skyrocketed by 1579300.0% to $15.8 million in 2023, then plummeted by 99.99% to $1000.0 in 2024, then soared by 240400.0% to $2.4 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $2.4 million, $1.9 million, and $4.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.